{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:51:47Z","timestamp":1793242307269,"version":"4.5.0"},"reference-count":30,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Takeda Farmac\u00e9utica Espa\u00f1a S.A."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Brentuximab vedotin (BV) has been shown to be effective in the treatment of classical Hodgkin\u2019s lymphoma (cHL), systemic anaplastic large cell lymphoma (sALCL), and CD30-positive cutaneous T-cell lymphoma (CTCL). This study aimed to evaluate the effectiveness and safety of BV retreatment in patients with relapsed\/refractory cHL, sALCL, and CD30-positive CTCL. Methods: This multicenter, non-interventional, retrospective medical chart review study analyzed medical records from 43 patients retreated with BV in Spain. Patients were included if they had relapsed or refractory cHL, sALCL, or CD30-positive CTCL and were previously treated with BV. Demographic characteristics, disease stage, response to treatment, survival outcomes, and adverse events were analyzed. Results: The study population included 16 patients with cHL, 13 with sALCL, and 14 with CTCL. The majority were male (58.1%) with a mean age of 46.2 years and baseline ECOG scores of 0\u20131. Among cHL and sALCL patients, disease stage, according to the Ann Arbor classification, ranged from I to IVB, while in CTCL, EORTC clinical stages ranged from IA to IVB. The overall response rate to BV retreatment was 76.7%, with the highest response observed in sALCL (92.3%). Complete remission was achieved in 60.5% of patients. Median progression-free survival was 25.4 months, and overall survival reached 50 months. Treatment failure occurred in 37.2% of patients. BV was generally well tolerated, with peripheral neuropathy being the most frequently reported adverse event. Conclusions: The BELIEVE study is the largest study to date demonstrating that retreatment with BV is an effective and well-tolerated option for patients with relapsed or refractory CD30-positive malignancies.<\/jats:p>","DOI":"10.3390\/cancers17071137","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T06:45:51Z","timestamp":1743144351000},"page":"1137","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Retreatment with Brentuximab Vedotin in Patients with Relapsed\/Refractory CD30+ Malignancies: A Retrospective Medical Chart Review Study in Spain-The BELIEVE Study"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1238-6970","authenticated-orcid":false,"given":"Anna","family":"Sureda","sequence":"first","affiliation":[{"name":"Intitut Catal\u00e0 d\u2019Oncologia, Duran i Reynals Hospital, IDIBELL, 08908 Hospitalet de Llobregat, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4120-2787","authenticated-orcid":false,"given":"Ram\u00f3n","family":"Garc\u00eda-Sanz","sequence":"additional","affiliation":[{"name":"CIBERONC, Institute of Cancer and Hematological Diseases, Gregorio Mara\u00f1\u00f3n General University Hospital, FiBGM, Dr. Esquerdo 46, 28007 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8907-090X","authenticated-orcid":false,"given":"Eva","family":"Domingo-Domenech","sequence":"additional","affiliation":[{"name":"Intitut Catal\u00e0 d\u2019Oncologia, Duran i Reynals Hospital, IDIBELL, 08908 Hospitalet de Llobregat, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Capote","sequence":"additional","affiliation":[{"name":"Puerta del Mar University Hospital, 11009 C\u00e1diz, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9062-077X","authenticated-orcid":false,"given":"Antonio","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Son Espases University Hospital, IdISBa, 07120 Islas Baleares, Palma, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6330-7729","authenticated-orcid":false,"given":"Antonia","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Hematology Department, 12 De Octubre University Hospital, 28041 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5623-9315","authenticated-orcid":false,"given":"David","family":"Aguiar","sequence":"additional","affiliation":[{"name":"Gran Canaria University Hospital Dr. Negrin, 35010 Las Palmas de Gran Canaria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8791-1901","authenticated-orcid":false,"given":"Pilar","family":"Giraldo","sequence":"additional","affiliation":[{"name":"Quironsalud Zaragoza Day Hospital, 50012 Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0096-9359","authenticated-orcid":false,"given":"Mar\u00eda Stefan\u00eda","family":"Infante","sequence":"additional","affiliation":[{"name":"Infanta Leonor University Hospital, 28031 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"L\u00f3pez-Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"Ram\u00f3n y Cajal University Hospital, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8401-7306","authenticated-orcid":false,"given":"Carmen","family":"Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"S\u00e1nchez-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Del Mar University Hospital, 08003 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo L.","family":"Ortiz-Romero","sequence":"additional","affiliation":[{"name":"Dermatology Department, 12 De Octubre University Hospital, Institute i+12, Medical School, Complutense University, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1181-9479","authenticated-orcid":false,"given":"Marta","family":"Grande","sequence":"additional","affiliation":[{"name":"Medical Departament, Takeda Farmac\u00e9utica Espa\u00f1a S.A., 28027 Madrid, Spain"},{"name":"Clinical Medicine, Alcal\u00e1 University, 28801 Alcal\u00e1 de Henares, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Baeza-Monta\u00f1ez","sequence":"additional","affiliation":[{"name":"Medical Departament, Takeda Farmac\u00e9utica Espa\u00f1a S.A., 28027 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"ref_1","unstructured":"Takeda (2025, February 18). Adcetris(R) (Brentuximab Vedotin) SmPc, Available online: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/112794001\/FT_112794001.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/17474086.2017.1281122","article-title":"Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic\/dendritic cell neoplasms","volume":"10","author":"Jiang","year":"2017","journal-title":"Expert Rev. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.clml.2023.10.001","article-title":"Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States","volume":"24","author":"Barta","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1756-8722-7-24","article-title":"Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies","volume":"7","author":"Bartlett","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/10428194.2019.1654100","article-title":"Retreatment with brentuximab vedotin in patients with relapsed\/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: A multicenter retrospective study","volume":"61","author":"Fukuhara","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"12003","DOI":"10.1182\/blood-2022-158225","article-title":"Efficacy and Safety of Retreatment with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or CD30-Expressing Peripheral T Cell Lymphoma","volume":"140","author":"Sano","year":"2022","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.3390\/curroncol31050195","article-title":"Brentuximab Vedotin Retreatment in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or Peripheral T-Cell Lymphoma: A Retrospective United States Claims Analysis","volume":"31","author":"Sano","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Munir, F., Hardit, V., Sheikh, I.N., AlQahtani, S., He, J., Cuglievan, B., Hosing, C., Tewari, P., and Khazal, S. (2023). Classical Hodgkin Lymphoma: From Past to Future\u2014A Comprehensive Review of Pathophysiology and Therapeutic Advances. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241210095"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41408-021-00518-z","article-title":"Latest advances in the management of classical Hodgkin lymphoma: The era of novel therapies","volume":"11","author":"Mohty","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1182\/blood.V96.12.3681","article-title":"CD30(+) anaplastic large cell lymphoma: A review of its histopathologic, genetic, and clinical features","volume":"96","author":"Stein","year":"2000","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/17474086.2017.1270202","article-title":"Diagnostic, prognostic and therapeutic role of CD30 in lymphoma","volume":"10","author":"Pierce","year":"2016","journal-title":"Expert Rev. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.critrevonc.2015.12.018","article-title":"Panoptic clinical review of the current and future treatment of relapsed\/refractory T-cell lymphomas: Cutaneous T-cell lymphomas","volume":"99","author":"Zinzani","year":"2016","journal-title":"Crit. Rev. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.36849\/JDD.6981e","article-title":"A Case Series on the Use of Brentuximab Vedotin for the Treatment of Mycosis Fungoides","volume":"22","author":"Kelly","year":"2023","journal-title":"J. Drugs Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/S0959-8049(22)00634-7","article-title":"Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry","volume":"173","author":"Muniesa","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_15","unstructured":"NCI (2017). Common Terminology Criteria for Adverse Events (CTCAE), U.S. Department of Health and Human Services."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1182\/blood-2012-03-418673","article-title":"Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma","volume":"119","author":"Chen","year":"2012","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2018","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1182\/bloodadvances.2021004710","article-title":"Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician\u2019s choice in cutaneous T-cell lymphoma: Final data","volume":"5","author":"Horwitz","year":"2021","journal-title":"Blood Adv."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study","volume":"30","author":"Pro","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","article-title":"Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"130","author":"Pro","year":"2017","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): An international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Randall, M.P., and Spinner, M.A. (2023). Optimizing Treatment for Relapsed\/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy. Cancers, 15.","DOI":"10.20944\/preprints202307.0430.v1"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chem-otherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin\u2019s Lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/blood-2011-12-397893","article-title":"Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation","volume":"120","author":"Gopal","year":"2012","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/7\/1137\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:04:16Z","timestamp":1760029456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/7\/1137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":30,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["cancers17071137"],"URL":"https:\/\/doi.org\/10.3390\/cancers17071137","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]}}}